NDAORALTABLET
Approved
Oct 2008
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
2/8 — Basic
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIMPAT (lacosamide) is a small-molecule antiepileptic drug approved in 2008 that selectively enhances slow inactivation of voltage-gated sodium channels to stabilize neuronal membranes and inhibit repetitive firing. It is indicated for partial-onset seizures in epilepsy patients and is administered orally with high bioavailability (~100%) and a 13-hour half-life. The drug shows dose-proportional pharmacokinetics with low inter-subject variability, supporting consistent dosing from 100-800 mg daily.
LOE ApproachingPost-LOE
As LOE approaches in April 2026, commercial teams face declining revenue and potential downsizing, making this a transition period for brand role stability.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Lacosamide in Neonates With Repeated Electroencephalographic Neonatal Seizures
Started Mar 2021
29 enrolled
Electroencephalographic Neonatal SeizuresEpilepsy
A Study to Test the Long-term Use of Oral Lacosamide in Pediatric Study Participants Who Completed NCT01964560 (EP0034) or NCT00938912 (SP848) and Received Lacosamide Treatment
Started Dec 2020
48 enrolled
Epilepsy
Evaluation of the Efficacy and Safety of Lacosamide in Pediatric Patients With Epilepsy
Started Nov 2019
300 enrolled
Epilepsy
A Study to Investigate the Bioequivalence of Lacosamide 200mg Administered as Intravenous Solution and Oral Tablet in Healthy Chinese Male Subjects
Started Jun 2017
30 enrolled
Healthy Male Chinese Volunteers
Study to Investigate Safety and Tolerability of Intravenous Lacosamide in Children.
Started May 2017
103 enrolled
Epilepsy
Worked on VIMPAT at UCB Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.